TScan Therapeutics, Inc. (TCRX)Healthcare | Biotechnology | Waltham, United States | NasdaqGM
0.75 USD
+0.00
(0.440%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.75 |
Hot Take ↕ | Aug. 22, 2026, 3:44 a.m. EDT
The immediate outlook is bearish as the stock trades significantly below its 50-day and 200-day moving averages, indicating persistent selling pressure despite a recent minor bounce. While the company recently reported improved net losses, the underlying business fundamentals remain deeply distressed with a massive contraction in revenue, negative operating margins, and severe cash burn. The multi-year price trajectory confirms a structural deterioration, having lost over 83% of its value since the start of the observation window, with the most recent annual period showing another sharp decline. There is no dividend income to offset these risks, and the balance sheet shows significant debt relative to equity. Although analysts maintain a 'strong buy' rating based on potential clinical trial data, the current financial reality and deteriorating revenue trend suggest the market has not yet priced in a successful turnaround, making this a high-risk speculative play rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.119594 |
| AutoETS | 0.121270 |
| MSTL | 0.122377 |
| AutoTheta | 0.188129 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.068 |
| Excess Kurtosis | -0.44 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 131.693 |
| Revenue per Share | 0.105 |
| Market Cap | 49,241,840 |
| Forward P/E | -0.81 |
| Beta | 1.07 |
| Website | https://www.tscan.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.57142854 |
| Address1 | 830 Winter Street |
| All Time High | 14.71 |
| All Time Low | 0.716 |
| Ask | 0.975 |
| Ask Size | 2 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 259,040 |
| Average Daily Volume3 Month | 598,372 |
| Average Volume | 598,372 |
| Average Volume10Days | 259,040 |
| Beta | 1.072 |
| Bid | 0.5418 |
| Bid Size | 2 |
| Book Value | 1.613 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.7535 |
| Current Ratio | 3.372 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.78 |
| Day Low | 0.75 |
| Debt To Equity | 131.693 |
| Display Name | TScan Therapeutics |
| Earnings Timestamp End | 1,762,954,200 |
| Earnings Timestamp Start | 1,762,954,200 |
| Ebitda | -115,660,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.361 |
| Enterprise To Revenue | 5.879 |
| Enterprise Value | 41,808,668 |
| Eps Current Year | -0.8725 |
| Eps Forward | -0.935 |
| Eps Trailing Twelve Months | -0.9 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.87002 |
| Fifty Day Average Change | -0.11651999 |
| Fifty Day Average Change Percent | -0.13392794 |
| Fifty Two Week Change Percent | -57.142853 |
| Fifty Two Week High | 2.57 |
| Fifty Two Week High Change | -1.8165 |
| Fifty Two Week High Change Percent | -0.70680934 |
| Fifty Two Week Low | 0.716 |
| Fifty Two Week Low Change | 0.037499964 |
| Fifty Two Week Low Change Percent | 0.05237425 |
| Fifty Two Week Range | 0.716 - 2.57 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,626,442,200,000 |
| Float Shares | 57,818,416 |
| Forward Eps | -0.935 |
| Forward P E | -0.80588233 |
| Free Cashflow | -79,923,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 138 |
| Fullday Change | 0.00330001 |
| Fullday Change Percent | 0.439884 |
| Fullday Price | 0.7535 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -88,323,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00189 |
| Held Percent Institutions | 0.62438 |
| Implied Shares Outstanding | 65,350,817 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. |
| Long Name | TScan Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 49,241,840 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_583057578 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -117,712,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 51,200,448 |
| Number Of Analyst Opinions | 4 |
| Open | 0.7551 |
| Operating Cashflow | -116,280,000 |
| Operating Margins | -29.01332 |
| Payout Ratio | 0.0 |
| Phone | 857 399 9500 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 0.7535 |
| Post Market Time | 1,787,947,805 |
| Previous Close | 0.7502 |
| Price Eps Current Year | -0.86361027 |
| Price Hint | 4 |
| Price To Book | 0.46714196 |
| Price To Sales Trailing12 Months | 6.9247417 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.235 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.00330001 |
| Regular Market Change Percent | 0.439884 |
| Regular Market Day High | 0.78 |
| Regular Market Day Low | 0.75 |
| Regular Market Day Range | 0.75 - 0.78 |
| Regular Market Open | 0.7551 |
| Regular Market Previous Close | 0.7502 |
| Regular Market Price | 0.7535 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 150,690 |
| Return On Assets | -0.31526 |
| Return On Equity | -0.95805 |
| Revenue Growth | -0.658 |
| Revenue Per Share | 0.105 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 61,074,229 |
| Shares Percent Shares Out | 0.023599999 |
| Shares Short | 1,601,066 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,384,530 |
| Short Name | TScan Therapeutics, Inc. |
| Short Percent Of Float | 0.0339 |
| Short Ratio | 3.02 |
| Source Interval | 15 |
| State | MA |
| Symbol | TCRX |
| Target High Price | 7.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 6.0 |
| Target Median Price | 6.0 |
| Total Cash | 100,156,000 |
| Total Cash Per Share | 1.478 |
| Total Debt | 90,893,000 |
| Total Revenue | 7,111,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.9 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.016385 |
| Two Hundred Day Average Change | -0.26288497 |
| Two Hundred Day Average Change Percent | -0.25864705 |
| Type Disp | Equity |
| Volume | 150,690 |
| Website | https://www.tscan.com |
| Zip | 2,451 |